Neo-adjuvant Chemo and immunotherapy with durvalumab (MEDI4736) and tremelimumab (MEDI1123) In The pre-operAtive Treatment of locally advanced cholangIOcarciNoma: an exploratory and translational study.

This trial is open to adults aged 18 and over who have been diagnosed with locally advanced bile duct cancer. Both men and women can take part. To join, a person's cancer must be in a stage where treatment before surgery is considered a safe and sensible next step by their medical team.

People will need to have a general health check to make sure their liver, kidneys, and heart are strong enough to handle chemotherapy and immunotherapy. Because these medicines are powerful, patients who are very frail, who have certain active autoimmune conditions, or who are pregnant may not be able to join.

Your cancer specialist will review your scans, medical history, and blood tests to confirm whether this trial is a suitable and safe option for you.

If you take part, you will receive treatment through a drip into a vein (an intravenous infusion) at a hospital clinic before your planned operation. The treatment includes standard chemotherapy medicines (gemcitabine and cisplatin) combined with immunotherapy drugs (durvalumab and tremelimumab). You will need to visit the hospital regularly for these infusions and for routine health checks.

During your visits, the healthcare team will run blood tests, check your vital signs, and carry out imaging scans (such as CT or MRI scans) to see how the cancer is responding. After finishing the course of medication, you will have your surgery as planned.

Following surgery, your care team will monitor your recovery closely. You will have regular follow-up appointments and scans over the course of at least 12 months to track your health and check that the cancer has not returned.